
Tyra Biosciences (TYRA) Stock Forecast & Price Target
Tyra Biosciences (TYRA) Analyst Ratings
Bulls say
Tyra Biosciences is poised for success with its cutting-edge precision medicine platform, SNAP, and promising product pipeline targeting FGFR-driven conditions. With strong potential for dabogratinib's success in the market and the company's in-house drug design capabilities, Tyra Biosciences could potentially become a leading player in the biotech industry.
Bears say
Tyra Biosciences is a clinical-stage biotechnology company that has potential drugs in its pipeline for targeted oncology and genetically defined conditions, but has yet to demonstrate best-in-class efficacy and safety that would validate its oral treatment option as an alternative for patients. The company's financial performance is currently uncertain and highly dependent on the results of their upcoming drug trials. However, if successful, Tyra Biosciences could generate significant upside and value in the urology and skeletal dysplasia markets.
This aggregate rating is based on analysts' research of Tyra Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Tyra Biosciences (TYRA) Analyst Forecast & Price Prediction
Start investing in Tyra Biosciences (TYRA)
Order type
Buy in
Order amount
Est. shares
0 shares